mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

Neurobiol Aging. 2008 Jul;29(7):1040-51. doi: 10.1016/j.neurobiolaging.2007.02.005. Epub 2007 Mar 13.

Abstract

Modulation of excessive glutamatergic transmission within the basal ganglia is considered as an alternative approach to reduce l-Dopa-induced dyskinesias (LIDs) in Parkinson's disease (PD). In this study receptor binding autoradiography of [3H]MPEP, a metabotropic glutamate receptor 5 (mGluR5) selective radioligand, was used to investigate possible changes in mGluR5 in the basal ganglia of l-Dopa-treated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys having developed LIDs compared to animals in which LIDs was prevented by adjunct treatments. LIDs were associated with an increase of mGluR5 specific binding in the posterior putamen and pallidum (+41% and +56%) compared to controls. By contrast, prevention of dyskinesias was associated with an important decrease of mGluR5 specific binding in these areas (-37% and -48%) compared with dyskinetic animals. Moreover, an upregulation (+34%) of mGluR5 receptor binding was seen in the anterior caudate nucleus of saline treated MPTP monkeys. This study is the first to provide evidence that enhanced mGluR5 specific binding in the posterior putamen and pallidum may contribute to the pathogenesis of LIDs in PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine*
  • Animals
  • Basal Ganglia / drug effects
  • Basal Ganglia / metabolism*
  • Female
  • Macaca fascicularis
  • Ovariectomy
  • Parkinsonian Disorders / chemically induced*
  • Parkinsonian Disorders / metabolism*
  • Receptor, Metabotropic Glutamate 5
  • Receptors, Metabotropic Glutamate / metabolism*
  • Tissue Distribution

Substances

  • Receptor, Metabotropic Glutamate 5
  • Receptors, Metabotropic Glutamate
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine